Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Psychiatric disorders – page 13

  • 546 clinical trials
  • 252 recruiting
  • 147 conditions
  • 26 countries

Conditions in this area

147 conditions with trials, the busiest first

Dementia Alzheimer's type87Major depression57Schizophrenia39Depression35Narcolepsy19Cognitive disorder18Bipolar disorder16Autism spectrum disorder15Insomnia15Post-traumatic stress disorder14Psychotic disorder14Drug use disorder13Alcohol use disorder12Attention deficit hyperactivity disorder9Dementia9Obstructive sleep apnoea syndrome9Brain injury8Irritable bowel syndrome8Phenylketonuria8Bipolar I disorder7Drug dependence7Hypersomnia7Lennox-Gastaut syndrome7Anorexia nervosa6+123

Clinical trials in Psychiatric disorders

546 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

546 clinical trials

Alcohol abuse

Recruiting

Study on Psilocybin-Assisted Therapy for Patients with Severe Alcohol Use Disorder

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dry Extract From Psilocybe Cubensis (15-25:1), Extraction Solvent: Methanol
  • Sponsor:Association Hospitaliere De Bruxelles Et De Schaerbeek Centre Hospitalier Universitaire Brugmann

Schizophrenia

Recruiting

Study on the Effects of Vortioxetine on Cognitive Function in Patients with Early Schizophrenia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Aripiprazole
  • Sponsor:Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla

Cognitive disorder

Recruiting

Study on the Long-Term Effects of Gadoxetic Acid, Gadoteridol, and Gadobenate Dimeglumine on Motor and Cognitive Functions in Healthy Adults

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Gadobutrol
  • Sponsor:Iqvia Rds France

Cognitive disorder

Recruiting

Study on Lithium Carbonate for Patients with TBR1-Related Neurocognitive Disorder

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lithium Carbonate
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Generalised anxiety disorder

Recruiting

Study on ITI-1284 for Patients with Generalized Anxiety Disorder Not Responding to Current Treatment

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Iti-1284
  • Sponsor:Intra-Cellular Therapies Inc.

Type 1 diabetes mellitus+1

Recruiting

Study on Lisdexamfetamine and Methylphenidate for Children with ADHD and Type 1 Diabetes

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Lisdexamfetamine Dimesylate
  • Sponsor:Medical University Of Lodz

Major depression

Recruiting

Study on Esketamine and Aripiprazole with Antidepressants for Treatment-Resistant Depression in Elderly Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aripiprazole
  • Sponsor:Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla

Drug use disorder

Recruiting

Study of daridorexant and buprenorphine combination treatment for patients with opioid use disorder

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Buprenorphine
  • Sponsor:Linkopings Universitet

Bipolar disorder

Recruiting

Esketamine Nasal Spray for Patients with Treatment-Resistant Bipolar Depression

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Esketamine
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Amyotrophic lateral sclerosis+2

Recruiting

Study on Cannabis Extract for Improving Quality of Life in Patients with Alzheimer's, Parkinson's, or ALS Using Dronabinol and Cannabidiol

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cannabidiol
  • Sponsor:Azienda Ospedaliero-Universitaria Maggiore Della Carita

Borderline personality disorder

Recruiting

Study on Oxytocin and Self-Compassion Training for Patients with Borderline Personality Disorder

Registered drug
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Oxytocin
  • Sponsor:Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

Heart disease congenital+1

Recruiting

Study on Allopurinol Sodium for Brain Injury Prevention in Newborns with Critical Congenital Heart Disease Undergoing Heart Surgery

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Allopurinol Sodium
  • Sponsor:Universitair Medisch Centrum Utrecht

Substances studied in this area

The therapies tested most often in Psychiatric disorders trials.

Sodium Chloride25 clinical trialsTrospium Chloride17 clinical trialsXanomeline Tartrate16 clinical trialsCannabidiol15 clinical trialsDry Extract From Psilocybe Cubensis (15-25:1), Extraction Solvent: Methanol14 clinical trialsFlorquinitau (18F)14 clinical trialsOxytocin13 clinical trialsAripiprazole12 clinical trialsFlorbetaben (18F)12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.